Document is current
Any future updates will be listed below
-
Authors
Xu, Yaling
Guo, Xiaojing
Han, Xiao
Hu, Xiangnan
Gao, Bin
Sun, Bo
Zhang, Huayan
-
Funding
Funding for this research was provided by:
Guangzhou Women and Children’s Medical Center Clinical Doctor Research Fund (2023BS006)
Guangzhou Science and Technology Bureau: 2024 Basic and Applied Basic Research Topic (2024A04J3994)
- License Information
-
More Information
Article History
Received: 15 December 2025
Accepted: 13 April 2026
First Online: 19 April 2026
Declarations
:
: Author Xiangnan Hu (XNH) is a co-inventor and patent holder for the adamantane sulfonamide derivative CQMUH-011 (Patent Application No. 201610818842.7, P.R.C) and therefore has a potential financial interest in its future commercial or clinical development. To ensure the objectivity and credibility of this study, XNH’s role was limited to the provision of the compound and manuscript review. All animal experiments, histological scoring, data acquisition, and statistical analyses were performed independently by other investigators who hold no patent rights and were strictly blinded to the experimental group allocations. All other authors declare no competing interests.
: The study protocol was approved by the Ethics Committees of Children’s Hospital of Fudan University (No.2024241) and Guangzhou Women and Children’s Medical Center (No.KTDW-2025-01500). All methods were performed in accordance with the relevant guidelines and regulations. This study is reported in accordance with the ARRIVE guidelines 2.0.
